Goldman Sachs expects a FDA-approved coronavirus vaccine in 2020

Everyone is patiently waiting for the coronavirus vaccine to be developed, and with scientists around the world working around the clock to get one made, the main question on everyone's mind is when can we expect one to be rolled out?

Investment bank Goldman Sachs says that they expect the Food and Drug Administration to approve of a coronavirus vaccine sometime this year, which would tee up Americans to receive an inoculation by July of next year. Daan Struyven, a senior economist at Goldman, told investors in a report this past Monday, "While highly uncertain, our baseline expectation is that a large number of vaccines eventually gain approval with at least one FDA approval this year."

Struyven referenced the 26 coronavirus vaccines that are currently undergoing trials, and that among the candidates about a dozen have reached Phase 2. Additionally, six are currently in Phase 3 of the trials, which is the last phase before FDA approval. Struyven also recognized the speed of which the coronavirus vaccine has been developed, "For context, it took hepatitis B - the disease with the largest number of attempts - decades to reach the number of developments COVID-19 has sparked in a few quarters."